International Collaborative Cancer Group (ICCG)

The ICCG is a European collaborative trials group which represents a successful partnership with the pharmaceutical industry.

The ICCG was initiated 22 years ago and receives grant funding from industry to run trials in breast and gastric cancer. The Group is chaired by Pierre Hupperets (University Hospital Maastricht, Netherlands) whilst the Data Centre, located at Charing Cross, London, is under the directorship of Charles Coombes. The Data Centre works in close collaboration with the Clinical Trials and Statistics Unit at the Institute of Cancer Research (ICR-CTSU), Sutton. The ICR-CTSU conducts the statistical analyses and also provides some data management support.

Current Trials:

• REACT - A Phase III Multicentre Double Blind Randomised Trial of Celecoxib Versus Placebo following Chemotherapy in Primary Breast Cancer Patients
• NEOCENT -A Neoadjuvant Study of Chemotherapy versus Endocrine Therapy in Postmenopausal Patients with Primary Breast Cancer

Closed Trials in long term follow up:

• IES - A Randomised Double-blind Trial in Postmenopausal Women with Primary Breast Cancer, who have received Adjuvant Tamoxifen for 2-3 years, comparing Subsequent Adjuvant Exemestane Treatment with further Tamoxifen (960EXE031 - C/13/96)
• DEVA - A Multicentre Randomised Trial of Sequential Epirubicin and Docetaxel versus Epirubicin in Node Positive Postmenopausal Breast Cancer Patients (ICCG C/14/96 DEVA, ISRCTN 89772270)
• High Dose - High dose therapy with PBSC support in poor risk primary breast cancer (C/10/92)
• Node Negative - Adjuvant CMF v FEC in women with node negative, poor-risk primary breast cancer (C/6/89)

Translational research:

• PathIES - A multicentre retrospective collection of pre-diagnositc, recurrence and contralateral breast carcinoma tumour blocks from women participating in the Intergroup Exemestane Study (IES).